|
HB 56 |
Allows pharmaceutical companies to rebate portions of copayments to multiple sclerosis patients without violating anti-kickback and anti-rebate laws |
|
 |
|
Current Bill Summary
|
|
- Prepared by Senate Research -
|
|
HCS/HB 56 - This act provides that the anti-kickback, anti-rebating and other prohibited financial incentive provisions of Section 191.905 shall not apply to pharmaceutical programs that rebate a portion of health insurance copayments and coinsurance to multiple sclerosis patients or others suffering from chronic conditions who have been prescribed medicines for which there are no generic equivalents.STEPHEN WITTE
|
|
|
|
|
|